Malik V, Keogan M, Gilham C, Duffy G, Ravi N, Reynolds J V
Dept of Clinical Surgery, St James's Hospital and Trinity College Dublin.
Ir J Med Sci. 2006 Oct-Dec;175(4):48-54. doi: 10.1007/BF03167967.
The aim was to evaluate the impact of FDG-PET scan on tumour staging and management decisions in oesophageal cancer.
One-hundred consecutive patients referred for consideration of surgery underwent a whole body FDG-PET scan in addition to CT imaging.
Based on CT scan, a curative approach could be considered in 62 patients. The PET scan altered regional nodal (N) staging in 16 patients overall, but did not alter management decisions. Metastatic status (M) was increased in 14 patients, with altered management in 10/62 (16%). Nine were downstaged, with management changed in 3/38 (8%). Seventeen patients underwent 19 additional tests to clarify findings on PET, in 15 patients (88%) the tests revealed no pathology.
FDG-PET alters M stage in 23% of patients and may impact on surgical decision-making. The spurious investigations and cost of the high false-positive rate of further tests is of concern.
目的是评估氟代脱氧葡萄糖正电子发射断层扫描(FDG-PET)对食管癌肿瘤分期及治疗决策的影响。
100例连续转诊考虑手术治疗的患者除接受CT成像外,还进行了全身FDG-PET扫描。
基于CT扫描,62例患者可考虑采用根治性治疗方法。PET扫描共使16例患者的区域淋巴结(N)分期发生改变,但未改变治疗决策。14例患者的转移状态(M)有所增加,其中10/62例(16%)的治疗方案发生改变。9例患者分期降低,其中3/38例(8%)的治疗方案改变。17例患者接受了19项额外检查以明确PET检查结果,15例患者(88%)的检查未发现病变。
FDG-PET使23%的患者M分期发生改变,可能影响手术决策。进一步检查的高假阳性率导致的不必要检查和费用令人担忧。